Create a free account to see ACCE Scores
Sign up for free to unlock scores, score breakdowns, and stock analysis.
AQST
↓ PDF (Pro)Aquestive Therapeutics Inc. Common Stock
HealthcareDrug Manufacturers - Specialty & GenericUnited StatesNASDAQ
$4.26
+2.03%today
MKT CAP
$530M
+3.1% · 1Y
Earnings History
-39.7%
+32.3%
-4.2%
-18.1%
Q1 '25
Q2 '25
Q3 '25
Q4 '25
Analyst Targets
Current price
$4.26
Low
$6.00
Analyst Mean
$8.89
High
$11.00
9 analystsStrong Buy
Full Financials
Trailing P/E-
Forward P/E-7.3x
EV/EBITDA-
Price/Sales-
Dividend Yield-
Revenue Growth YoY-
Earnings Growth YoY-
Revenue Growth QoQ+1.6%
5y Revenue CAGR-2.2%
5y Earnings CAGR-
Gross Margin-
Operating Margin-
Net Margin-
ROE-
Debt / Equity-
Free Cash Flow-
Insider Ownership3.5%
Institutional Ownership60.8%
Short % of Float13.08%
Days to Cover11.0d
1 Week+2.5%
1 Month-
3 Months-
6 Months-
YTD-
1 Year-
3 Years-
5 Years-
vs 50-day SMA-
vs 200-day SMA-
vs 52w High-
vs 52w Low-
Insider Transactions
| Filer | Role | Type | Shares | Price | Value | Date |
|---|---|---|---|---|---|---|
| TOTH A ERNEST JR | Chief Financial Officer | Sale | 58,254 | $4.17 | $0.24M | 2026-03-10 |
| BARBER DANIEL R | Chief Executive Officer | Sale | 180,677 | $4.17 | $0.75M | 2026-03-10 |
| BOYD PETER E | Officer | Sale | 29,814 | $4.17 | $0.12M | 2026-03-10 |
| BRAENDER LORI J | Officer | Sale | 40,102 | $4.17 | $0.17M | 2026-03-10 |
| JUNG CASSIE | Chief Operating Officer | Sale | 45,791 | $4.17 | $0.19M | 2026-03-10 |
Top Holders
| Holder | Type | % Held | Value | Δ Shares | As of |
|---|---|---|---|---|---|
| Bratton Capital Management, LP | institution | 7.89% | $0.04B | +0.00% | 2025-12-31 |
| Blackrock Inc. | institution | 6.26% | $0.03B | +19.15% | 2025-12-31 |
| RTW Investments LP | institution | 5.03% | $0.03B | +0.00% | 2025-12-31 |
| Vanguard Group Inc | institution | 4.74% | $0.03B | +4.07% | 2025-12-31 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | fund | 2.65% | $0.01B | -4.59% | 2025-12-31 |
| EcoR1 Capital, LLC | institution | 2.11% | $0.01B | +0.00% | 2025-12-31 |
| Samsara BioCapital, LLC | institution | 2.01% | $0.01B | +0.00% | 2025-12-31 |
| iShares Trust-iShares Russell 2000 ETF | fund | 1.99% | $0.01B | -3.75% | 2026-03-31 |
| State Street Corporation | institution | 1.98% | $0.01B | +53.71% | 2025-12-31 |
| Geode Capital Management, LLC | institution | 1.91% | $0.01B | +13.42% | 2025-12-31 |
| Federated Hermes, Inc. | institution | 1.64% | $0.01B | +159.36% | 2025-12-31 |
| Morgan Stanley | institution | 1.42% | $0.01B | +24.72% | 2025-12-31 |
| Federated Hermes MDT Series-Federated Hermes MDT Small Cap Core Fund | fund | 1.12% | $0.01B | +31.26% | 2026-01-31 |
| Fidelity Salem Street Trust-Fidelity Small Cap Index Fund | fund | 0.82% | $0.00B | +0.84% | 2026-02-28 |
| VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund | fund | 0.79% | $0.00B | -3.39% | 2025-12-31 |
| WASATCH FUNDS TRUST-Wasatch Ultra Growth Fund | fund | 0.69% | $0.00B | +27.82% | 2026-03-31 |
| SPDR SERIES TRUST-State Street SPDR S&P Pharmaceuticals ETF | fund | 0.48% | $0.00B | -9.80% | 2026-03-31 |
| iShares Trust-iShares Russell 2000 Value ETF | fund | 0.47% | $0.00B | +0.46% | 2026-03-31 |
| abrdn Healthcare Investors | fund | 0.45% | $0.00B | +29.02% | 2025-12-31 |
| VANGUARD SCOTTSDALE FUNDS-Vanguard Russell 2000 Index Fund | fund | 0.42% | $0.00B | +22.62% | 2026-02-28 |
| Ticker | Cap | Score | P/E | Fwd P/E | EV/EBITDA | ROE | Gross | D/E | Div |
|---|---|---|---|---|---|---|---|---|---|
| BIOA | $820M | - | - | - | - | -27.1% | 0% | 2.04 | 0.00% |
| ETON | $833M | 60 | - | 16.4 | - | - | - | - | 0.00% |
| PCRX | $937M | 58 | 193.0 | 7.0 | - | - | - | - | 0.00% |
| CRON | $990M | 5 | - | - | - | - | - | - | 0.00% |
| AMPH | $1.1B | 100 | 11.8 | 6.9 | - | - | - | - | 0.00% |
| XERS | $1.1B | 60 | 94.7 | 17.0 | - | - | - | - | 0.00% |
Peers selected by sector + industry + nearest market cap. Best in column highlighted green, worst red.
Unlock Full Financials
Growth metrics, valuation multiples, and profitability ratios on Starter+.
Recent Alerts
No alerts yet for AQST.
Want deep analysis?
This stock isn't in the ACCE researched universe. Browse 300+ stocks with full thesis, scores, and financial models.
Browse ACCE Indices →Get the ACCE weekly digest
Index returns, picks recap, score movers - every Sunday. No fluff.